MT-103 Micromet/MedImmune

    Research output: Contribution to journalArticlepeer-review


    Micromet AG and MedImmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia. © The Thomson Corporation.
    Original languageEnglish
    Pages (from-to)62-68
    Number of pages6
    JournalCurrent Opinion in Molecular Therapeutics
    Issue number1
    Publication statusPublished - Feb 2006


    Dive into the research topics of 'MT-103 Micromet/MedImmune'. Together they form a unique fingerprint.

    Cite this